Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue

Harm Reduction Therapeutics, which has sought funding for a US Rx-to-OTC new drug application, receives grant from Purdue Pharma that enables filing and launching the product in a targeted 100,000 retail locations within two years.